Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?

Digestive and Liver Disease

Volumn 48, Issue 2, 2016, Pages 105-111

  Vanni, Ester ^a   Bugianesi, Elisabetta ^a   Saracco, Giorgio ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Chronic hepatitis C; Diabetes mellitus; Hepatitis C virus; Impaired fasting glucose; Insulin resistance; Interferon; Microangiopathy; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; CYTOKINE; GLUCOSE BLOOD LEVEL;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; DISEASE ASSOCIATION; FATTY LIVER; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; MICROANGIOPATHY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; VIRAL CLEARANCE; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HEPATITIS C, CHRONIC; IMMUNOLOGY; LIVER; METABOLISM; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BLOOD GLUCOSE; CYTOKINES; DIABETES MELLITUS, TYPE 2; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER; TREATMENT OUTCOME;

EID: 84957803843     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.10.016     Document Type: Review

References (100)

1. Seeff L.B. Natural history of chronic hepatitis C. Hepatology 2002, 36(Suppl. 1):S35-S46.
2. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C infection. Journal of Hepatology 2011, 55:245-264.
3. Gumber S.C., Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Annals of Internal Medicine 1995, 123:615-620.
4. Johnson R.J., Gretch D.R., Yamabe H., et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. New England Journal of Medicine 1993, 328:465-470.
5. Pawlotsky J.M., Roudot-Thoraval F., Simmonds P., et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Annals of Internal Medicine 1995, 122:169-173.
6. Boadas J., Rodríguez-Espinosa J., Enríquez J., et al. Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C infection. Journal of Hepatology 1995, 22:611-615.
7. Agnello V., Chung R.T., Kaplan L.M. A role for hepatitis C virus infection in type II cryoglobulinemia. New England Journal of Medicine 1992, 327:1490-1495.
8. Mostafa A., Mohamed M.K., Saeed M., et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010, 59:1135-1140.
9. Adinolfi L.E., Restivo L., Zampino R., et al. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opinion on Pharmacotherapy 2011, 12:2215-2234.
10. Lonardo A., Adinolfi L.E., Restivo L., et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World Journal of Gastroenterology 2014, 20:7089-7103.
11. Lonardo A., Loria P., Adinolfi L.E., et al. Hepatitis C and steatosis. Journal of Viral Hepatitis 2006, 13:73-80.
12. Meissner E.G., Lee Y.J., Sims Z., et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology 2015, 61:790-801.
13. Mehta S.H., Brancati F.L., Sulkowski M.S., et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C infection in the United States. Annals of Internal Medicine 2000, 133:592-599.
14. Mehta S.H., Brancati F.L., Strathdee S.A., et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003, 38:50-56.
15. White D.L., Ratziu V., El-Serag H.B. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. Journal of Hepatology 2008, 49:831-844.
16. Eslam M., Khattab M., Harrison S.A. Insulin resistance and hepatitis C: an evolving story. Gut 2011, 60:1139-1151.
17. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. Journal of Hepatology 2014, 61:S69-S78.
18. Kaddai V., Negro F. Current understanding of insulin resistance in hepatitis C. Expert Review of Gastroenterology & Hepatology 2011, 5:503-516.
19. Kawaguchi T., Yoshida T., Harada M., et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signalling 3. American Journal of Pathology 2004, 165:1499-1508.
20. Persico M., Russo R., Persico E., et al. SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells. Clinical Chemistry and Laboratory Medicine 2009, 47:1217-1225.
21. Pazienza V., Vinciguerra M., Andriulli A., et al. Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-γ in Huh-7 cells. Journal of General Virology 2010, 91:1678-1686.
22. Vanni E., Abate M.L., Gentilcore E., et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009, 50:697-706.
23. Milner K.L., van der Poorten D., Trenell M., et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010, 138:932-941.
24. Lemoine M., Chevaliez S., Bastard J.P., et al. Association between IL28Bpolymorphism, TNFα and biomarkers of insulin resistance in chronic hepatitis C-related insulin resistance. Journal of Viral Hepatitis 2015, 22:890-896.
25. Peta V., Torti C., Milic N., et al. Adiponectin serum level in chronic hepatitis C infection and therapeutic profile. World Journal of Hepatology 2015, 7:44-52.
26. Bernsmeier C., Calabrese D., Heim M.H., et al. Hepatitis C virus dysregulates glucose homeostasis by a dual mechanism involving induction of PGC1α and dephosphorylation of FoxO1. Journal of Viral Hepatitis 2014, 21:9-18.
27. Wójcik K., Jabłonowska E., Omulecka A., et al. Insulin resistance, adipokine profile and hepatic expression of SOCS-3 gene in chronic hepatitis C. World Journal of Gastroenterology 2014, 20:10449-10456.
28. Chen L., Liu W., Lai S., et al. Insulin resistance, serum visfatin and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus infected patients. European Journal of Gastroenterology and Hepatology 2013, 25:935-941.
29. Khattab M.A., Eslam M., Aly M.M., et al. Association of serum adipocytokines with insulin resistance and liver injury in patients with chronic hepatitis C genotype 4. Journal of Clinical Gastroenterology 2012, 46:871-879.
30. Corbetta S., Redaelli A., Pozzi M., et al. Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection. European Journal of Clinical Investigation 2011, 41:898-905.
31. Nkontchou G., Bastard J.P., Ziol M., et al. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. Journal of Hepatology 2010, 53:827-833.
32. Lonardo A., Adinolfi L.E., Petta S., et al. Hepatitis C and diabetes: the inevitable coincidence?. Expert Review of Anti-infective Therapy 2009, 7:293-308.
33. Ratziu V., Munteanu M., Charlotte F., et al. Fibrogenic impact of high serous glucose in chronic hepatitis C. Journal of Hepatology 2003, 39:1049-1055.
34. Hickman I.J., Powell E.E., Prins J.B., et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. Journal of Hepatology 2003, 39:1042-1048.
35. Hui J.M., Sud A., Farrell G.C., et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003, 125:1695-1704.
36. Muzzi A., Leandro G., Rubbia-Brandt L., et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. Journal of Hepatology 2005, 42:41-46.
37. Bugianesi E., Marchesini G., Gentilcore E., et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006, 44:1648-1655.
38. Kita Y., Mizukoshi E., Takamura T., et al. Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Metabolism: Clinical and Experimental 2007, 56:1682-1688.
39. Cua I.H., Hui J.M., Kench J.G., et al. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008, 48:723-731.
40. Huang J.F., Yu M.L., Dai C.Y., et al. Pretreatment insulin sensitivity contributes to the treatment response to peginterferon plus ribavirin combination therapy for patients with chronic hepatitis C. Hepatology 2007, 46(Suppl. 1):349A.
41. Romero-Gómez M., Del Mar Viloria M., Andrade R.J., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-641.
42. D'Souza R., Sabin C.A., Foster G.R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. American Journal of Gastroenterology 2005, 100:1509-1515.
43. Persico M., Capasso M., Persico E., et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 2007, 46:1009-1015.
44. Poustchi H., Negro F., Hui J., et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. Journal of Hepatology 2008, 48:28-34.
45. Chu C.J., Lee S.D., Hung T.H., et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Alimentary Pharmacology and Therapeutics 2009, 29:46-54.
46. Lai M.S., Hsieh M.S., Chiu Y.H., et al. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006, 43:1295-1302.
47. Tazawa J., Maeda M., Nakagawa M., et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Digestive Diseases and Sciences 2002, 47:710-715.
48. Veldt B.J., Chen W., Heathcote E.J., et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008, 47:1856-1862.
49. Donadon V., Balbi M., Zanette G. Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus. Expert Review of Gastroenterology & Hepatology 2009, 3:465-467.
50. Giordanino C., Ceretto S., Bo S., et al. Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study. Digestive and Liver Disease 2012, 44:406-412.
51. Hung C.H., Lee C.M., Wang J.H., et al. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. International Journal of Cancer 2011, 128:2344-2352.
52. Simó R., Lecube A., Genescà J., et al. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006, 29:2462-2466.
53. Kawaguchi T., Ide T., Taniguchi E., et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. American Journal of Gastroenterology 2007, 102:570-576.
54. Kawaguchi Y., Mizuta T., Oza N., et al. Eradication of hepatitis C virus by interferon improves whole-body insulin resistance and hyperinsulinemia in patients with chronic hepatitis C. Liver International 2009, 29:871-877.
55. Romero-Gómez M., Fernández-Rodríguez C.M., Andrade R.J., et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. Journal of Hepatology 2008, 48:721-727.
56. Delgado-Borrego A., Jordan S.H., Negre B., et al. Reduction of insulin resistance with effective clearance of Hepatitis C infection: results from the HALT-C trial. Clinical Gastroenterology and Hepatology 2010, 8:458-462.
57. Thompson A.J., Patel K., Chuang W.L., et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 2012, 61:128-134.
58. Aghemo A., Prati G.M., Rumi M.G., et al. A sustained virological response prevents development of insulin resistance in chronic hepatitis C patients. Hepatology 2012, 56:1681-1687.
59. Arase Y., Suzuki F., Suzuki Y., et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009, 49:739-744.
60. Giordanino C., Bugianesi E., Smedile A., et al. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. American Journal of Gastroenterology 2008, 103:2481-2487.
61. Garcia-Compean D., Jaquez-Quintana J.O., Gonzalez-Gonzalez J.A., et al. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World Journal of Gastroenterology 2009, 15:280-288.
62. Petrides A.S. Liver disease and diabetes mellitus. Diabetes Reviews 1994, 2:2-19.
63. Kruszynska Y.T., Harry D.S., Bergman R.N., et al. Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients. Diabetologia 1993, 36:121-128.
64. Visnegarwala F., Chen L., Raghavan S., et al. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. Journal of Infection 2005, 50:331-337.
65. Lecube A., Hernández C., Genescà J., et al. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 2004, 27:1171-1175.
66. Ruhl C.E., Menke A., Cowie C.C., et al. Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology 2014, 60:1139-1149.
67. Mangia A., Schiavone G., Lezzi G., et al. HCV and diabetes mellitus: evidence for a negative association. American Journal of Gastroenterology 1998, 93:2363-2367.
68. Lonardo A., Carulli N., Loria P. HCV and diabetes: a two-question-based reappraisal. Digestive and Liver Disease 2007, 39:753-761.
69. Moucari R., Asselah T., Cazals-Hatem D., et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV-RNA level, and liver fibrosis. Gastroenterology 2008, 134:416-423.
70. Stepanova M., Lam B., Younossi Y., et al. Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. Journal of Viral Hepatitis 2012, 19:341-345.
71. Cusi K. The relationship between hepatitis C virus infection and diabetes: time for a divorce?. Hepatology 2014, 60:1121-1123.
72. Marchesini G., Ronchi M., Forlani G., et al. Cardiovascular disease in cirrhosis: a point-prevalence study in relation to glucose tolerance. American Journal of Gastroenterology 1999, 94:655-662.
73. Holstein A., Hinze S., Thiessen E., et al. Clinical implications of hepatogenous diabetes in liver cirrhosis. Journal of Gastroenterology and Hepatology 2002, 17:677-681.
74. Kuriyama S., Miwa Y., Fukushima H., et al. Prevalence of diabetes and incidence of angiopathy in patients with chronic viral liver disease. Journal of Clinical Biochemistry and Nutrition 2007, 40:116-122.
75. Chehadeh W., Kurien S.S., Abdella N., et al. Hepatitis C virus infection in a population with high incidence of type 2 diabetes: impact on diabetes complications. Journal of Infection and Public Health 2011, 4:200-206.
76. Coppo C., Bonfanti D., Bo S., et al. Risk of microangiopathy in type 2 diabetes mellitus patients with or without chronic hepatitis C. Results of a retrospective long-term controlled cohort study. Digestive and Liver Disease 2015, 47:405-410.
77. Adinolfi L.E., Restivo L., Marrone A. The predictive value of steatosis in hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology 2013, 7:205-213.
78. Czaja A.J., Carpenter H.A., Santrach P.J., et al. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. Journal of Hepatology 1998, 29:198-206.
79. Bugianesi E., Salamone F., Negro F. The interaction of metabolic factors with HCV infection: does it matter?. Journal of Hepatology 2012, 56:S56-S65.
80. Rubbia-Brandt L., Quadri R., Abid K., et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. Journal of Hepatology 2000, 33:106-115.
81. Kumar D., Farrell G.C., Fung C., et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: genotype-specific reversal of hepatic steatosis after sustained response to antiviral therapy. Hepatology 2002, 36:1266-1272.
82. Poynard T., Ratziu V., McHutchison J., et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75-85.
83. Fraser A., Harris R., Sattar N., et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009, 32:741-750.
84. Park S.K., Seo M.H., Shin H.C., et al. The clinical availability of non-alcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-years prospective cohort study. Hepatology 2013, 57:1378-1383.
85. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
86. Adinolfi L.E., Restivo L., Zampino R., et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 2012, 221:496-502.
87. Adinolfi L.E., Restivo L., Guerrera B., et al. Chronic HCV infection is a risk factor of ischemic stroke. Atherosclerosis 2013, 231:22-26.
88. Hsu Y.C., Lin J.T., Ho H.J., et al. Antiviral treatment for hepatitis C Virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014, 59:1293-1302.
89. Donadon V., Balbi M., Valent F., et al. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World Journal of Gastroenterology 2010, 16:3025-3032.
90. Feng B., Eknoyan G., Guo Z.S., et al. Effect of interferon-alpha-based therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. Nephrology, Dialysis, Transplantation 2012, 27:640-646.
91. Alberti K.G., Zimmet P., Shaw J., et al. The metabolic syndrome - a new worldwide definition. Lancet 2005, 366:1059-1062.
92. Pansuria M., Xi H., Li L., et al. Insulin resistance, metabolic stress, and atherosclerosis. Frontiers in Bioscience (Schol Ed) 2012, 4:916-931.
93. Pasterkamp G. Methods of accelerated atherosclerosis in diabetic patients. Heart 2013, 99:743-749.
94. Yuan X.M., Li W. Iron involvement in multiple signalling pathways of atherosclerosis: a revisited hypothesis. Current Medicinal Chemistry 2008, 15:2157-2172.
95. Petit J.M., Minello A., Jooste V., et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. Journal of Clinical Endocrinology and Metabolism 2005, 90:2240-2243.
96. Cua I.H., Hui J.M., Bandara P., et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007, 46:66-73.
97. Targher G., Bertolini L., Padovani R., et al. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. Journal of Hepatology 2007, 46:1126-1132.
98. Petta S., Torres D., Fazio G., et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 2012, 55:1317-1323.
99. Masiá M., Padilla S., Robledano C., et al. Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study. BMC Infectious Diseases 2011, 11:265.
100. Petta S., Macaluso F.S., Craxì A. Cardiovascular diseases and HCV infection: a simple association or more?. Gut 2014, 63:369-375.